Abstract
Introduction

One of the emerging cardiovascular risk factors is subclinical chronic low-grade inflammation [1]. Population studies showed a strong correlation between pro-inflammatory biomarkers (such as C-reactive protein, interleukin-6 [IL-6] and tumour necrosis factor-␣ [TNF-␣]) and perturbations in glucose homeostasis, obesity and atherosclerosis [2, 3]. Another emerging risk factor is oxidized lowdensity lipoprotein (ox-LDL) that activates circulating monocytes, thereby increasing their ability to infiltrate the vascular wall. This increased infiltration is a key event in atherogenesis [4].
The metabolic syndrome clusters several cardiovascular risk factors including obesity, dyslipidaemia, hypertension and insulin resistance (IR) [5] [6] [7] [8] . Increased inflammation [9, 10] and oxidative stress [11, 12] were found to be associated with the metabolic syndrome. It is a primary risk factor for diabetes and cardiovascular diseases [6, [13] [14] [15] [16] [17] [18] [19] [20] [22, 23] . This enhanced infiltration is causatively related to the loss of insulin signalling [24] . The [33] .
. Recent data suggest that increased oxidative stress in adipose tissue is an early instigator of the metabolic syndrome and that the redox state in adipose tissue is a potentially useful therapeutic target for the obesity-associated metabolic syndrome [21]. Oxidative damage of adipose tissues is associated with impaired adipocyte maturation, production of pro-inflammatory adipocytokines by dysfunctional adipocytes and increased infiltration of macrophages into the adipose tissues of obese persons where they produce inflammatory chemokines
Activated macrophages secrete a number of growth factors such as the macrophage colony-stimulating factor (M-CSF) that augments SR-A expression, and induces the production of cytokines and growth factors which stimulate intimal proliferation. Once resident in the arterial wall, the interaction between monocytes/macrophages and T cells results in a broad range of cellular and humoural responses that drive the progression of a relatively simple fatty streak to a more complex lesion. Modified forms of LDL are immunogenic and activate both cellmediated and humoural immune responses. Both types of responses are pro-inflammatory and are probably primary players in the perpetuation of the chronic inflammatory reaction characteristic of atherosclerosis. The immunologic response to modified LDL can be directed to major histocompatibilty complex class II (MHC-II)-associated peptides in the case of T helper cells, and to a variety of epitopes-modified lysine groups, modified phospholipids, proteins that become associated with ox-LDL (such as ␤2 glycoprotein 1) -in the case of B cell responses [34]. At the other hand, the activation of regulatory T cells may be protective. Indeed, recent data showed that alum precipitates, containing antigens derived from ox-LDL, increased regulatory T cells activated by tolerogenic antigen-presenting cells presenting ox-LDL antigens [35]. Similarly macrophages, endothelial cells and smooth muscle cells (SMCs) appear to be activated, demonstrated by increased expression of MHC-II molecules, and of toll-like receptors (TLRs) of which the ligands induce the release of numerous inflammatory products, such as TNF-␣, IL-6 and MCP-1. Recently, we found that ox-LDL can also induce inflammation by inducing TLR-2 and -4 and the interferon regulatory factor-1 [36] (Fig. 1).
Moreover, activated macrophages produce pro-inflammatory secretory phospholipase A (2) (sPLA (2) (Fig. 1) . (Fig. 2) .
Furthermore, activation of inflammatory cells is associated with the activation of sphingomyelinases (SMS) in the trans-Golgi apparatus and in plasma membranes resulting in the synthesis of sphingomyelin (SM), which transfers the phosphorylcholine moiety from phosphatidylcholine onto ceramide [44]. The interaction between SM, cholesterol, and glycosphingolipid drives the formation of SM-enriched lipid rafts resulting in an inhibition of the
Fig. 1 Molecular mechanisms of inflammation and oxidative stress in atherosclerotic plaques. Endothelial dysfunction in relation to hypercholesterolemia, hypertension, type 2 diabetes, and smoking is associated with induction of adhesion molecules for inflammatory cells, ICAM-1, VCAM-1, E-selectin and fibronectin. The infiltration and activation of inflammatory cells are associated with the activation of the oxidant enzymes MPO and NOX-1, resulting in the production of ROS and the oxidation of phospholipids and protein in LDL, resulting in the accumulation of ox-LDL. It stimulates the endothelium to secrete MCP-1 and IL-8, which induce transmigration of leucocytes into the endothelial space. Macrophages secrete M-CSF, thereby stimulating macrophage proliferation and inducing the expression of scavenger receptors CD36, LOX-1 and SR-A. The scavenger receptor mediated uptake of ox-LDL by macrophages leads to massive cholesterol and lipid accumulation and formation of foam cells, finally resulting in apoptotic macrophages and exposure of thrombogenic lipids. Deficient TSP-1 expression is associated with a decreased phagocytosis of dead cells. Foam cells secrete MMPs and SMS resulting in the production of ceramide that induces smooth SMC apoptosis (black cells). Activation of SMS also blunts the action of ABCA-1 and ABCG-1 resulting in impaired cholesterol and lipid efflux from foam cells. Ox-LDL induces TLRs of which the ligands enhance the expression of inflammatory mediators IL-6 and TNF-␣. Ox-LDL induces migration inhibitory factor that stimulates SMC migration. The uptake of ox-LDL by SMCs leads to the production of SMC foam cells and secretion of MMPs
Regulatory mechanisms of interactions between oxidative stress and inflammation
Recently, we obtained a mouse model of the metabolic syndrome that allowed the study of molecular mechanisms explaining the relations of the metabolic syndrome components with enhanced inflammation and oxidative stress. Indeed, we found that mice with combined leptin and LDL receptor deficiency (double knockout [DKO] mice) are obese and show severe hypertriglyceridaemia, hypertension and IR and diabetes. This combination of metabolic syndrome factors was associated with accelerated atherosclerosis due to increased accumulation of macrophages in association with endothelial dysfunction demonstrated by increased expression of VCAM-1 and ICAM-1 in the aorta of DKO mice [49]. Increased macrophage accumulation was associated with elevated plaque ox-LDL. The latter could be partly attributed to increased MPO by plaque macrophages. In addition, impaired high-density lipoprotein associated anti-oxidant activity in the blood [50] was associated with more ox-LDL in the plaques. We then investigated the relation between metabolic syndrome components and the oxidation of LDL further by assessing the effect of weight loss. We selected this intervention because it had been demonstrated that the cardiovascular risk of insulin-resistant obese persons is higher than that of insulin-sensitive obese persons, and that weight loss reduces the risk of insulin-resistant
PPAR-␥ also increases CD36-mediated clearance of ox-LDL. The decrease of ox-LDL is associated with a reduction of the TLRmediated inflammatory response. PPAR-␥ also decreases expressions of monocyte-specific adhesion molecules and chemotactic factors, resulting in less macrophage accumulation. In addition, PPAR-␥ increases NOS production associated with improved endothelial function, induces the efflux of cholesterol and lipids from foam cells by up-regulating the liver X receptors (LXR)-␣ and ABCA-1. Finally, PPAR-␥ induces the expressions of the glucose transporter-4 and the insulin receptor substrate-2 (IRS-2), which activate glucose uptake and insulin action. The improved IRS-2-mediated insulin signalling is associated with increased SOD-2 expression, resulting in lower mitochondrial oxidative stress and ROS production. Finally, PPAR-␥ activation was found to prime monocytes into alternative M2 macrophages with anti-inflammatory properties [55].
Overview of molecular mechanisms explaining the association of inflammation and oxidative stress in adipose tissues
Obesity is associated with reduced adipose tissue oxygenation and hypoxia, without the appropriate angiogenic response, due to defective activation of LXRs [56] and vascular endothelial growth factor (VEGF) [57] , but with increased macrophage chemotaxis [23] (Fig. 3) [60] . [62] [63] [64] [67] . This resolution is impaired in obesity leading to defective protection against oxidative stress-initiated inflammation by glutathione conjugates of lipid oxidation-derived aldehydes, such as 4-hydroxy-trans-2-nonenal present in ox-LDL [68] .
Infiltrated inflammatory cells produce and secrete TNF-␣ and IL-6 contributing to the pathogenesis of IR, together with factors produced by dysfunctional adipocytes such as leptin and resistin. Conversely, insulin-sensitizing adiponectin is downregulated during obesity [61]. A range of mouse models with loss-of-function mutations in genes important in macrophage recruitment (MCP-1 and chemokine (C-C motif) receptor 2), inflammatory cytokine production (TNF-␣) and pro-inflammatory activation (NF-B [nuclear factor of light polypeptide gene enhancer in B-cells] and IB kinase [IKK]␤) have demonstrated to be protected against high-fat diet-induced IR
A possible explanation for the relation between ox-LDL and obesity is that ox-LDL increases the volume of adipose tissues either directly by inducing adipocyte proliferation [69] or indirectly by increasing the infiltration of inflammatory monocytes/macrophages which increase adipogenesis [70] . The increase in adipose tissue mass may also be explained by a cellular hypertrophy due to an increased lipid accumulation in the pre-existing adipocytes rather than an increase in cell number or differentiation. Indeed, ox-LDL increases triglyceride production by inducing the expression of lipoprotein lipase [71] , and the accumulation of fatty acids in adipocytes [72] . Interestingly, fatty acids stimulate the accumulation of ceramide that contributes to inflammation that, as discussed above, is associated with adipose hyperplasia. Ox-LDL was also found to decrease the production of adiponectin that in contrast with other adipocytokines is reduced in obese persons, and suppresses excess ROS production under high-glucose conditions, an effect that has implications for vascular protection in diabetes [73] . In addition, the decrease of adiponectin results in a loss of its capacity to protect cells against inactivation of the growth arrest specific 6 mediated survival pathway by TNF-␣ [74] . The observed relations between obesity and ox-LDL are important to understand the relation of obesity with IR [27] and the metabolic syndrome [75] . All these processes are summarized in Fig. 3 . 
